Schleis Thomas G
Northwest Medical Specialties, PLLC, Tacoma, Washington, USA.
Pharmacotherapy. 2005 Nov;25(11 Pt 2):73S-77S. doi: 10.1592/phco.2005.25.11part2.73S.
From the transmission of hepatitis C virus by gammaglobulins in 1994 to the emergence of new viruses and concern over prions, intravenous immunoglobulin (IGIV) manufacturers have continued to address safety issues and respond to changing needs. New IGIV products not only provide superior antiviral safety, but also show advances in product purity and manufacturing processes. Several manufacturers have also addressed the concern over prion transmission. The sum of the processes used have collectively ensured continuous product safety. Newer products will be further differentiated by their tolerability and efficacy profiles.
从1994年丙型肝炎病毒通过丙种球蛋白传播到新病毒的出现以及对朊病毒的担忧，静脉注射免疫球蛋白（IGIV）制造商一直在持续解决安全问题并应对不断变化的需求。新型IGIV产品不仅提供了卓越的抗病毒安全性，而且在产品纯度和生产工艺方面也有进步。几家制造商还解决了对朊病毒传播的担忧。所采用的一系列工艺共同确保了产品的持续安全性。更新的产品将因其耐受性和疗效特征而进一步差异化。
